Here, people with RA that did not sufficiently respond to a previous therapy with TNFα inhibitors, secukinumab was superior to placebo in two of the studies (but numerically less efficacious as abatcept, an active comparator) and not superior to placebo in the second study [29]. Here, TNF is linked to rheumatoid arthritis.